The approval of semaglutide 2.4mg (Wegovy) in 2021 and tirzepatide 15mg (Zepbound) in 2023 has fundamentally changed the landscape of obesity medicine. These GLP-1 receptor agonists (and in tirzepatide's case, dual GLP-1/GIP agonism) produce sustained weight loss of 15–22% body weight over 68 weeks in pivotal trials — outcomes previously achievable only with bariatric surgery. The clinical implications for healthcare facilities managing patients with obesity and its metabolic comorbidities are profound. Supporting these patients requires comprehensive clinical management including appropriate monitoring supplies and nutrition support from our medical supply catalog.
Mechanisms of Action
GLP-1 (glucagon-like peptide-1) is a gut-derived incretin hormone that acts on GLP-1 receptors in the pancreas (stimulating glucose-dependent insulin secretion), hypothalamus (producing satiety signaling and appetite suppression), gastric enteric nervous system (slowing gastric emptying), and the hindbrain/nucleus tractus solitarius (CNS reward pathway modulation reducing food reward). Semaglutide's 168-hour half-life (vs endogenous GLP-1's 2-minute half-life) sustains these effects continuously with weekly dosing. Tirzepatide adds GIP receptor agonism, which synergizes with GLP-1 activity to produce greater caloric intake reduction and significantly higher mean weight loss (20–22% at maximum dose vs 15% for semaglutide).
Patient Selection and Monitoring
FDA-approved indications: BMI ≥30 kg/m² (obesity), or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications: personal or family history of medullary thyroid carcinoma or MEN2 syndrome (black box warning — thyroid C-cell tumors in rodent studies); pancreatitis history (relative). Monitoring: A1C, fasting glucose, lipid panel, kidney function at baseline and follow-up; thyroid evaluation; GI adverse effect management. The primary adverse effects — nausea, vomiting, diarrhea — are dose-dependent and manageable with slow dose escalation. Monitoring supplies including blood glucose meters and diagnostic testing are available from our diagnostic equipment section.
Nutritional Considerations During GLP-1 Therapy
The dramatic caloric restriction produced by GLP-1 receptor agonists creates nutritional challenges: patients consuming 500–1000 fewer calories daily require close attention to protein adequacy (sarcopenia prevention), micronutrient sufficiency (B12, folate, iron — paralleling post-bariatric concerns), and hydration (nausea-related decreased fluid intake). Protein supplementation targeting 1.2–1.5g/kg/day becomes more critical as caloric intake decreases. High-protein oral nutritional supplements, protein powder, and clinical nutrition products are available through our nutrition catalog. Registered dietitian involvement is an important component of comprehensive GLP-1 therapy programs.
